Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 07-Sep-2018

Novel drug delivery system


One of the biggest problems in cancer treatment is that chemotherapy kills cancer cells, but also kills healthy cells along the way. Using nanotechnology, we are developing a novel drug delivery platform that carries biotherapies to specifically targeted parts of the body and release the drugs in appropriate places. In 2016 drug delivery system market size was valued $510B with annual growth rate of 6.9% and is expected to reach approximately $900B by 2025. Unlike the present drug delivery platforms in the market, our technology has the advantage of being biodegradable, harmless to humans, cheap to produce and can avoid body’s immune defenses.

Additional Questions

Who is your customer?

Pharmaceutical companies and Research laboratories.

What problem does this idea/product solve or what market need does it serve?

The present drug delivery platform in the market is so non-specific that allows chemotherapy to kill cancer as well as healthy cells leading to loss of hair and render patients susceptible to infections. We provide a better solution since our engineered drug delivery platform and the technology behind it has the advantage of being biodegradable and harmless to humans and can avoid body's immune defenses.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Our drug delivery platform is superior because it shielded the active pharmaceutical ingredient (API) thereby protecting the payload from rapid clearance by the reticuloendothelial system. Furthermore, our drug drug delivery platform will minimize the non-selective targeting of bystander cells because it displays the normal repertoire of body constituents therefore avoiding harmful responses of the body's immune defenses.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

The President and founder Souvenir Tachado, MD is an immunologist and have done research at Harvard Medical School. He has experience in biopharmaceuticals and one prior start-up. Seyha Seng, PhD has done prostate cancer research at Harvard Medical School. He has experience in biopharmaceutical and one start-up. We already tested and validated the technology and worked very well in the lab and planning to test in animal models.